Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis

Ouellet, 2002, Truncated hemoglobin HbN protects Mycobacterium bovis from nitric oxide, Proc Natl Acad Sci USA, 99, 5902, 10.1073/pnas.092017799 Kilinc, 2002, Risk of tuberculosis among healthcare workers, Respir Med, 96, 506, 10.1053/rmed.2002.1315 Deol, 1997, Lung specific stealth liposomes, Biochim Biophys Acta, 1334, 161, 10.1016/S0304-4165(96)00088-8 Quenelle, 2001, Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid, Antimicrob Agents Chemother, 45, 1637, 10.1128/AAC.45.6.1637-1644.2001 Dutt, 2001, Therapeutic efficacy of poly (dl-lactide-co-glycotide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice, Antimicrob Agents Chemother, 45, 363, 10.1128/AAC.45.1.363-366.2001 Jiao, 2002, In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits, Circulation, 105, 230, 10.1161/hc0202.101988 Ahlin, 2002, Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration, Int J Pharm, 239, 113, 10.1016/S0378-5173(02)00076-5 Horisawa, 2002, Prolonged anti-inflammatory action of dl-lactide/glycolide copolymer nanospheres containing betamethazone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit, Pharm Res, 19, 403, 10.1023/A:1015123024113 Jacobs, 2002, Production and characterisation of a budesonide nanosuspension for pulmonary administration, Pharm Res, 19, 189, 10.1023/A:1014276917363 Anderson, 1997, Biodegradation and biocompatibility of PLA and PLGA microspheres, Adv Drug Deliv Rev, 28, 5, 10.1016/S0169-409X(97)00048-3 Lamprecht, 1999, Biodegradable monodispersed nanoparticles prepared by pressure homogenisation-emulsification, Int J Pharm, 184, 97, 10.1016/S0378-5173(99)00107-6 Saito, 1989, Therapeutic efficacy of liposome entrapped rifampicin against Mycobacterium avium complex infections induced in mice, Antimicrob Agents Chemother, 33, 429, 10.1128/AAC.33.4.429 Scott, 1967, Fluorimetric determination of isonicotinic acid hydrazide in plasma, J Lab Clin Med, 70, 355 Gurumurthy, 1980, Methods for the estimation of pyrazinamide and pyrazinoic acid in body fluids, Indian J Med Res, 71, 129 Govender, 2000, Defining the drug incorporation properties of PLA-PEG nanoparticles, Int J Pharm, 199, 95, 10.1016/S0378-5173(00)00375-6 Grandfils, 1996, Control of the biodegradation rate of poly (dl-lactide) microparticles intended as chemoembolization materials, J Controlled Release, 38, 109, 10.1016/0168-3659(95)00102-6 Ain, 2002, Role of poly [dl-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s), Int J Pharm, 239, 37, 10.1016/S0378-5173(02)00034-0 Mathiowitz, 1997, Biologically erodable microspheres as potential oral drug delivery systems, Nature, 386, 410, 10.1038/386410a0 Dutt, 2001, Chemotherapy of Mycobacterium tuberculosis infection in mice with a combination of isoniazid and rifampicin entrapped in poly (dl-lactide-co-glycolide) microparticles, J Antimicrob Chemother, 47, 829, 10.1093/jac/47.6.829 Dalencon, 1997, Atovaquone and rifabutine-loaded nanocapsules, Int J Pharm, 153, 127, 10.1016/S0378-5173(97)00076-8 Lopes, 2000, Polymeric colloidal systems containing ethionamide, Pharmazie, 55, 527